Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,767 public trials 494 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

NCT00055562

Conditions
Melanoma, Neoplasm Metastasis, Neoplasms, +13 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Southern California Norris Cancer Center Los Angeles, California, United States
  • UCLA Los Angeles, California, United States
  • St. Francis Memorial Hospital San Francisco, California, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04708418

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Melanoma of Unknown Primary, +15 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
View all 188 locations
View Trial Details
Active, Not Recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 839 locations
View Trial Details
Active, Not Recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

NCT02506153

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +18 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Virginia G Piper Cancer Care-Del Camino Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 576 locations
View Trial Details
Active, Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144

Conditions
Adnexal Diseases, Breast Carcinoma, Breast Diseases, +70 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

NCT02339571

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +11 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • CARTI Cancer Center Little Rock, Arkansas, United States
  • John L McClellan Memorial Veterans Hospital Little Rock, Arkansas, United States
View all 764 locations
View Trial Details
Active, Not Recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338

Conditions
Melanoma, Melanoma of Unknown Primary, Neoplasms, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Regional Hospital Anchorage, Alaska, United States
View all 938 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1411 locations
View Trial Details

Related conditions